Clinical Trials Logo

Filter by:
NCT ID: NCT01243177 Completed - Epilepsy Clinical Trials

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

SP0993
Start date: April 2011
Phase: Phase 3
Study type: Interventional

Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom. Noninferiority design to show a similar risk/benefit balance between Lacosamide (LCM) and Carbamazepine-CR (CBZ-CR).

NCT ID: NCT01233622 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

Vildagliptin
Start date: October 2010
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with Type 2 Diabetes (T2D).

NCT ID: NCT01232569 Completed - Clinical trials for Rheumatoid Arthritis

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Start date: March 2011
Phase: Phase 3
Study type: Interventional

This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.

NCT ID: NCT01231607 Completed - Clinical trials for Androgenetic Alopecia

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

Start date: October 28, 2010
Phase: Phase 3
Study type: Interventional

The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

NCT ID: NCT01225952 Completed - Cataract Clinical Trials

Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The objective of this study is to compare the contrast sensitivity, high and low contrast visual acuity (VA), glare meter outcomes, and subject satisfaction with three different FDA-approved intraocular lenses (IOLs) designed to improve distance, intermediate, and near vision following lens extraction in adults at least 40 years of age.

NCT ID: NCT01225562 Completed - Stroke Clinical Trials

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

PEGASUS
Start date: October 2010
Phase: Phase 3
Study type: Interventional

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

NCT ID: NCT01223456 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

ONGLYZA PMS
Start date: October 2010
Phase: N/A
Study type: Observational

This post marketing surveillance study aims to monitor the safety and efficacy of ONGLYZA under conditions of actual use in patients who are diagnosed with diabetes mellitus type 2 and are prescribed ONGLYZA by their physician.

NCT ID: NCT01219114 Withdrawn - Clinical trials for Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis

Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

Start date: October 2010
Phase: N/A
Study type: Observational

The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are prescribed CUBICIN by their physician.

NCT ID: NCT01218906 Completed - Fever Clinical Trials

Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia

Start date: August 2010
Phase: N/A
Study type: Observational

The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a Phase 3 efficacy trial of a vaccine to prevent dengue infection. The primary objectives are: - To identify acute febrile episodes among the cohort in order to detect the presence of dengue infection. - To develop operational infrastructure for potential Phase III dengue efficacy trial sites. - To describe the dengue seroprevalence among the cohort at baseline and at the end of the study.

NCT ID: NCT01218308 Completed - Influenza Clinical Trials

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Start date: December 9, 2010
Phase: Phase 3
Study type: Interventional

This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to Havrix®, a licensed Hepatitis A virus vaccine. This study will also evaluate the immunogenicity and safety of the investigational vaccine.